- Home
- WYNN vs ABVX Comparison
WYNN vs ABVX Comparison
Compare WYNN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WYNN | ABVX |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 11.9B |
| IPO Year | 2002 | 2022 |
Fundamental Metrics
Financial Performance| Metric | WYNN | ABVX |
|---|---|---|
| Price | $81.28 | $92.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $142.73 | $131.31 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-07-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $6,717,660,000.00 | N/A |
| Revenue This Year | $6.49 | $52.14 |
| Revenue Next Year | $4.58 | $4,132.27 |
| P/E Ratio | $33.98 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $77.06 | $69.81 |
| 52 Week High | $134.72 | $148.83 |
Technical Indicators
Market Signals| Indicator | WYNN | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 27.48 | 28.09 |
| Support Level | N/A | $72.30 |
| Resistance Level | $107.47 | $130.96 |
| Average True Range (ATR) | 2.38 | 4.66 |
| MACD | -0.40 | -1.74 |
| Stochastic Oscillator | 27.34 | 1.63 |
Price Performance
Historical ComparisonAbout WYNN Wynn Resorts Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming rooms and attractions in Macao over the next few years, including a new 432-suite tower adjacent to its Palace resort opening in 2029. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.